Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fosinopril + losartan is a combination of two antihypertensive agents, each with distinct mechanisms of action. Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in decreased aldosterone secretion, reduced sodium and water retention, and increased bradykinin levels leading to vasodilation[8][3][5]. Losartan is an angiotensin II receptor blocker (ARB) that selectively blocks the binding of angiotensin II to the type 1 (AT1) receptor on vascular smooth muscle and adrenal gland tissues, preventing vasoconstriction and aldosterone-mediated effects[10][6][5]. The combination may provide additive or synergistic effects in lowering blood pressure and reducing proteinuria but carries a risk for significant drug interactions such as hyperkalemia or renal impairment; thus, it should only be used under close medical supervision[2][7][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fosinopril + losartan.